5
Kareems Spun Silk Ltd
514294 BSE
Kareems Spun Silk Ltd
BSE: 514294
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Kareems Spun Silk Ltd insights
49 extracted metrics + investor summaries across FY06–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Weaknesses
2- Company has low interest coverage ratio.
- Company has high debtors of 166 days.
Growth Rate
Revenue Growth
-
Net Income Growth
-100.00% →
Cash Flow Change
-
ROE
-
ROCE
-
EBITDA Margin (Avg.)
-
Quarterly Results
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,407 | 6,473 | 6,851 | 7,219 | 7,352 | 7,580 | 7,567 | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 | 8,646 |
| Expenses | 5,453 | 5,477 | 5,702 | 5,846 | 5,753 | 5,920 | 5,949 | 6,230 | 6,401 | 6,622 | 6,265 | 6,608 | 6,873 |
| Operating Profit | 954 | 996 | 1,149 | 1,373 | 1,599 | 1,660 | 1,618 | 1,566 | 1,578 | 1,760 | 1,603 | 1,678 | 1,773 |
| OPM % | 15% | 15% | 17% | 19% | 22% | 22% | 21% | 20% | 20% | 21% | 20% | 20% | 21% |
| Other Income | 93 | 135 | 47 | 188 | 163 | 14 | 221 | 136 | 159 | 135 | 107 | 122 | 123 |
| Interest | 45 | 56 | 57 | 68 | 76 | 89 | 111 | 113 | 118 | 115 | 98 | 95 | 93 |
| Depreciation | 321 | 346 | 327 | 418 | 423 | 354 | 404 | 382 | 419 | 444 | 406 | 429 | 465 |
| PBT | 680 | 730 | 812 | 1,076 | 1,262 | 1,230 | 1,324 | 1,207 | 1,200 | 1,335 | 1,207 | 1,276 | 1,339 |
| Tax % | 28% | 31% | 30% | 30% | 26% | 26% | 31% | 32% | 30% | 32% | 32% | 34% | 32% |
| Net Profit | 491 | 506 | 570 | 752 | 940 | 907 | 918 | 817 | 846 | 903 | 824 | 848 | 910 |
| EPS in Rs | 8.38 | 8.64 | 9.74 | 12.92 | 15.98 | 15.51 | 15.69 | 14.07 | 14.56 | 15.56 | 14.2 | 14.61 | 15.67 |
Profit & Loss
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2017 | Mar 2018 | |
|---|---|---|---|---|---|---|
| Sales | 0.07 | 0.29 | 1.22 | 1.37 | 0 | 0.11 |
| Expenses | 0.19 | 0.52 | 1.67 | 1.34 | 0.15 | 0.18 |
| Operating Profit | -0.12 | -0.23 | -0.45 | 0.03 | -0.15 | -0.07 |
| OPM % | -171.43% | -79.31% | -36.89% | 2.19% | — | -63.64% |
| Other Income | -0.05 | 0 | 0.03 | 0 | 0.15 | 0.04 |
| Interest | 0 | 0 | 0 | 0.02 | 0 | 0 |
| Depreciation | 0.53 | 0.53 | 0.53 | 0.53 | 0 | 0 |
| PBT | -0.7 | -0.76 | -0.95 | -0.52 | 0 | -0.03 |
| Tax % | 0% | 0% | 0% | 0% | — | -33.33% |
| Net Profit | -0.7 | -0.76 | -0.95 | -0.52 | -0.01 | -0.02 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2017 | Mar 2018 | |
|---|---|---|---|---|---|---|
| Equity Capital | 6.47 | 6.47 | 6.47 | 6.47 | 6.47 | 6.47 |
| Reserves | -7.28 | -6.83 | -8.02 | -8.54 | -10.81 | -10.83 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 7.2 | 6.64 | 7.67 | 8.48 | 5 | 5.14 |
| Total Liabilities | 6.39 | 6.28 | 6.12 | 6.41 | 0.66 | 0.78 |
| Fixed Assets | 4.85 | 4.36 | 3.88 | 3.36 | 0.55 | 0.55 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1.54 | 1.92 | 2.24 | 3.05 | 0.11 | 0.23 |
| Total Assets | 6.39 | 6.28 | 6.12 | 6.41 | 0.66 | 0.78 |
Cash Flow
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2017 | Mar 2018 | |
|---|---|---|---|---|---|---|
| Operating | -0.3 | -0.73 | -1.02 | -0.54 | 0.04 | -0.03 |
| Investing | 0.33 | 0.73 | 1 | 0.58 | 0 | 0 |
| Financing | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 0.03 | 0 | -0.02 | 0.04 | 0.04 | -0.03 |
| Free Cash Flow | 0.03 | -0.77 | -1.04 | -0.5 | 0.04 | -0.03 |
| CFO/OP | 250 | 317 | 227 | -1,800 | -27 | 43 |
Ratios
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2017 | Mar 2018 | |
|---|---|---|---|---|---|---|
| Debtor Days | 4,641 | 1,284 | 479 | 639 | — | 166 |
| Inventory Days | 4,928 | 702 | 99.55 | 114 | 0 | 0 |
| Days Payable | 1,03,295 | 7,749 | 2,367 | 3,166 | — | — |
| Cash Conversion Cycle | -93,727 | -5,764 | -1,789 | -2,413 | — | 166 |
| Working Capital Days | -29,774 | -6,004 | -1,634 | -1,465 | — | -16,027 |
Documents
1
Clarification On Media Report, 'Aurobindo Pharma'S P Sarath Chandra Reddy Acquitted In Delhi Liquor Scam Case'.
2 Mar - P. Sarath Chandra Reddy discharged by Delhi court in CBI Delhi Liquor case on 27-Feb-2026. 2 Mar - P. Sarath Chandra Reddy discharged by Delhi court in CBI Delhi Liquor case on 27-Feb-2026.
3
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
12h - Of investor meet to be held on 13.03.2026. 12h - Of investor meet to be held on 13.03.2026.
4
Completion Of US FDA Inspection At Unit I Of Eugia Pharma Specialities Ltd
27 Feb - US FDA inspected Eugia Pharma Unit‑I (Aurobindo subsidiary) Feb 16–27, 2026; inspection closed with four observations. 27 Feb - US FDA inspected Eugia Pharma Unit‑I (Aurobindo subsidiary) Feb 16–27, 2026; inspection closed with four observations.
5
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2m - Submission of press release on launch of Pomalidomide Capsules 1 mg, 2 mg, 3 mg and 4 mg in the US market by Eugia Pharma … 2m - Submission of press release on launch of Pomalidomide Capsules 1 mg, 2 mg, 3 mg and 4 mg in the US market by Eugia Pharma …
Frequently Asked Questions about Kareems Spun Silk Ltd
Where is Kareems Spun Silk Ltd (514294) listed?
Kareems Spun Silk Ltd is listed on the Indian stock exchanges. It is listed on BSE: 514294. You can view its live share price, financials, and ratios on Tapetide.
How can I research Kareems Spun Silk Ltd on Tapetide?
On Tapetide, you can view Kareems Spun Silk Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Face Value ₹ 10